A Multi-Center, Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects with Huntington Disease

… Enrollment for DIMOND has been completed as of March 2008 …

The Huntington Study Group (HSG) conducted a study of the research medication dimebon in persons 29 years of age or older who had mild to moderate Huntington disease (HD).  DIMOND was designed to determine safe and tolerable doses of dimebon and also to determine the effect of dimebon on cognitive (thinking) and motor (movement) signs and overall functioning of subjects with HD. Sixteen research centers in the United States and one research center in the United Kingdom enrolled 91 research subjects. The time on study drug was 3 months. The study enrolled research subjects with early to moderate signs of HD who were independently ambulatory (walking) and self-sufficient in activities of daily living, such as eating, dressing, and bathing.  Enrollment began in the Summer of 2007, and was completed in March 2008.  The study was sponsored by Medivation, Inc.

For further information please contact the Huntington Study Group toll free (from the US and Canada) at 1-800-487-7671.

Related Documents:
DIMOND Participating Site List
July 2007 DIMOND Press Release
October 2006 DIMOND Press Release

Related Links: 
March 2009 Poster Presentation "The Safety and Efficacy of Dimebon in Mild-to-Moderate Huntington's Disease: A Multicenter, Phase 2, Randomized, Placebo-Controlled Trial (DIMOND)", 9th International Conference AD/PD 2009 in Prague, Czech Republic
July 2008 Medivation Press Release About the DIMOND Top-Line Results
July 2008 Commentary by Marsha Miller, PhD about Medivation's Top-Line Results Press Release
ClinicalTrials.gov
January 2008 HDSA DIMOND News Article by Marsha Miller, PhD

last updated: July 2009